MX2020006818A - Receptores quimericos multiespecificos que comprenden un dominio nkg2d, y metodos de uso de los mismos. - Google Patents

Receptores quimericos multiespecificos que comprenden un dominio nkg2d, y metodos de uso de los mismos.

Info

Publication number
MX2020006818A
MX2020006818A MX2020006818A MX2020006818A MX2020006818A MX 2020006818 A MX2020006818 A MX 2020006818A MX 2020006818 A MX2020006818 A MX 2020006818A MX 2020006818 A MX2020006818 A MX 2020006818A MX 2020006818 A MX2020006818 A MX 2020006818A
Authority
MX
Mexico
Prior art keywords
domain
methods
nkg2d
chimeric receptors
nkg2d domain
Prior art date
Application number
MX2020006818A
Other languages
English (en)
Inventor
Jun Wang
Xiaohu Fan
Pingyan Wang
Qiuchuan Zhuang
Lian Ma
Original Assignee
Nanjing Legend Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotech Co Ltd filed Critical Nanjing Legend Biotech Co Ltd
Publication of MX2020006818A publication Critical patent/MX2020006818A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4234—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/15—Non-antibody based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proveen receptores quimericos que focalizan a NKG2D y receptores quiméricos multiespecificos que comprenden un dominio NKG2D y un segundo dominio de union a antigeno tal como un dominio de IL-3; se proveen tambien sistemas de receptores quimericos dobles que comprenden un primer receptor quimerico que comprende un dominio NKG2D, y un segundo receptor quimerico que comprende un segundo dominio de union a antigeno tal como un dominio de IL-3; se proveen ademas celulas efectoras inmunes disenadas (tales como celulas T), composiciones farmaceuticas, kits y metodos de tratamiento del cancer.
MX2020006818A 2017-12-28 2018-12-28 Receptores quimericos multiespecificos que comprenden un dominio nkg2d, y metodos de uso de los mismos. MX2020006818A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2017/119397 WO2019127215A1 (en) 2017-12-28 2017-12-28 Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
PCT/CN2018/124978 WO2019129220A1 (en) 2017-12-28 2018-12-28 Multispecific chimeric receptors comprising nkg2d domain and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2020006818A true MX2020006818A (es) 2021-01-08

Family

ID=67063249

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006818A MX2020006818A (es) 2017-12-28 2018-12-28 Receptores quimericos multiespecificos que comprenden un dominio nkg2d, y metodos de uso de los mismos.

Country Status (14)

Country Link
US (1) US20210363218A1 (es)
EP (1) EP3732192A4 (es)
JP (1) JP7379803B2 (es)
KR (1) KR20200103703A (es)
CN (3) CN114656569B (es)
AU (1) AU2018396969A1 (es)
BR (1) BR112020013211A2 (es)
CA (1) CA3086932A1 (es)
IL (1) IL275512A (es)
MX (1) MX2020006818A (es)
RU (1) RU2020120853A (es)
SG (1) SG11202005584TA (es)
TW (1) TW201930342A (es)
WO (2) WO2019127215A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210014210A (ko) 2014-05-15 2021-02-08 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
CA3056439A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
AU2018245749A1 (en) 2017-03-27 2019-10-03 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
SG11202007156QA (en) * 2018-02-09 2020-08-28 Nat Univ Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
US12486514B2 (en) 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN120624368A (zh) * 2019-08-29 2025-09-12 克莱格医学有限公司 抗移植反应的细胞和方法
CN113583127A (zh) * 2020-04-30 2021-11-02 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用
JP2023532973A (ja) * 2020-07-03 2023-08-01 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 多官能直交タンパク質キメラ
IL300225A (en) * 2020-07-31 2023-03-01 Chugai Pharmaceutical Co Ltd A pharmaceutical composition including chimeric receptor expressing cells
IL308696A (en) * 2021-05-24 2024-01-01 Kite Pharma Inc Nkg2d-based chimeric antgen receptor
CN117736335A (zh) * 2022-09-20 2024-03-22 深圳先进技术研究院 靶向间皮素和nkg2d配体的双靶向car-t细胞及其应用
WO2024153124A1 (zh) * 2023-01-18 2024-07-25 南京传奇生物科技有限公司 经修饰的原代t细胞及其用途
WO2025006631A1 (en) * 2023-06-27 2025-01-02 Nkarta, Inc. Dosing regimens for treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
SG10202006507XA (en) * 2012-05-30 2020-08-28 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule
WO2014117121A1 (en) * 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
ES3034398T3 (en) * 2014-08-28 2025-08-18 Bioatla Inc Conditionally active chimeric antigen receptors for modified t-cells
HK1246180A1 (zh) * 2014-12-31 2018-09-07 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
AR100680A1 (es) * 2015-01-26 2016-10-26 Macrogenics Inc Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos
EP4272757A3 (en) * 2015-06-10 2023-12-27 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
US11667691B2 (en) * 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3373952A4 (en) * 2015-11-10 2019-05-22 Fred Hutchinson Cancer Research Center NKG2D decoys
EP3373970A4 (en) * 2015-11-13 2019-07-10 Dana Farber Cancer Institute, Inc. NKG2D IG FUSION PROTEIN FOR CANCER IMMUNOTHERAPY
CN105647873A (zh) * 2016-03-14 2016-06-08 紫程瑞生会(北京)生物技术发展有限公司 一种双特异性嵌合抗原受体基因修饰的自然杀伤细胞的制备方法及其试剂盒
CN109311963A (zh) * 2016-04-14 2019-02-05 蓝鸟生物公司 救助嵌合抗原受体系统
CA3056439A1 (en) * 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
CN107326014B (zh) * 2017-07-31 2019-09-24 时力生物科技（北京）有限公司 一种双特异性嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用

Also Published As

Publication number Publication date
BR112020013211A2 (pt) 2021-09-28
WO2019127215A1 (en) 2019-07-04
CN114656570B (zh) 2024-03-01
KR20200103703A (ko) 2020-09-02
WO2019129220A1 (en) 2019-07-04
US20210363218A1 (en) 2021-11-25
EP3732192A1 (en) 2020-11-04
AU2018396969A1 (en) 2020-07-02
CA3086932A1 (en) 2019-07-04
CN114656569B (zh) 2024-01-30
JP7379803B2 (ja) 2023-11-15
CN111836827B (zh) 2022-02-01
CN111836827A (zh) 2020-10-27
RU2020120853A (ru) 2022-01-28
JP2021508463A (ja) 2021-03-11
CN114656569A (zh) 2022-06-24
SG11202005584TA (en) 2020-07-29
IL275512A (en) 2020-08-31
EP3732192A4 (en) 2022-05-04
CN114656570A (zh) 2022-06-24
TW201930342A (zh) 2019-08-01

Similar Documents

Publication Publication Date Title
MX2020006818A (es) Receptores quimericos multiespecificos que comprenden un dominio nkg2d, y metodos de uso de los mismos.
MX2022015823A (es) Receptores de antigenos quimerlcos basados en anticuerpos de dominio simple y metodos de uso de estos.
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
PH12018500861A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
MX2023006482A (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
PH12019501440A1 (en) Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
WO2018234793A3 (en) Antibodies
EP4506036A3 (en) Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
AU2018278321A1 (en) Chimeric antigen receptors targeting FLT3
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
EP4223269A3 (en) Uses of anti-bcma chimeric antigen receptors
EP4273258A3 (en) Proteins binding her2, nkg2d and cd16
PH12016501680B1 (en) Anti-egfrviii antibodies and uses thereof
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
EP4541819A3 (en) Anti-cd3 epsilon antibodies
AU2018279184A1 (en) Anti-TrkB antibodies
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
EP4467565A3 (en) Anti-tnf alpha antibody formulations
WO2018227063A8 (en) Anti-robo2 antibodies, compositions, methods and uses thereof
MX2019005933A (es) Polipeptidos biespecificos para gitr y ctla-4.
WO2020014505A3 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
WO2022115565A3 (en) Chimeric receptors and methods of use thereof
WO2020014542A3 (en) Compositions and methods related to engineered fc-antigen binding domain constructs